For patients where heart disease is the primary concern alongside weight, the cardiovascular trial evidence behind Wegovy is currently more developed
BoujedidiHRobertOBignonACassard-DoulcierAMRenoudMLGary-GouyHet al
The comparative effects of perindopril and catechin on mesangial matrix and podocytes in the streptozotocin induced diabetic rats
Three further Phase 3 trial results in the TRIUMPH programme are due before the end of 2026: TRIUMPH-2 in obesity with type 2 diabetes, TRIUMPH-3 in obesity with established cardiovascular disease (with further safety information relevant to higher-risk populations), and obstructive sleep apnoea
Abbreviations ESKD: End-stage kidney disease GLP-1 RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure ICER: Incremental cost-effectiveness ratio MI: Myocardial infarction NDSS: National Diabetes Services Scheme QALY: Quality-adjusted life year SGLT2i: Sodiumglucose co-transporter 2 inhibitor References McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
For some patients, using both makes sense
